Prehospital ticagrelor in ST-segment elevation myocardial infarction

New England Journal of Medicine

Volumn 371, Issue 11, 2014, Pages 1016-1027

  Montalescot, Gilles ^a   Van't Hof, Arnoud W ^f   Lapostolle, Frédéric ^d   Silvain, Johanne ^a   Lassen, Jens Flensted ⁱ   Bolognese, Leonardo ^j   Cantor, Warren J ^k   Cequier, Ángel ^m   Chettibi, Mohamed ⁿ   Goodman, Shaun G ^l   Hammett, Christopher J ^o   Huber, Kurt ^p   Janzon, Magnus ^q   Merkely, Béla ^r   Storey, Robert F ^s   Zeymer, Uwe ^t   Stibbe, Olivier ^b   Ecollan, Patrick ^a   Heutz, Wim M J M ^g   Swahn, Eva ^q   Collet, Jean Philippe ^a   Willems, Frank F ^h   Baradat, Caroline ^e   Licour, Muriel ^e   Tsatsaris, Anne ^e   Vicaut, Eric ^c   Hamm, Christian W ^u   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Brigade de Sapeurs Pompiers Paris   (France)

^c ACTION Study Group   (France)

^d The Department of Anesthesia and Intensive Care Medicine   (France)

^e ASTRAZENECA   (United Kingdom)

^f ISALA HOSPITAL   (Netherlands)

^g Regionale Ambulance Voor ziening Gelderland Midden   (Netherlands)

^h RIJNSTATE HOSPITAL   (Netherlands)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j Azienda Ospedaliera Arezzo   (Italy)

^k SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ Centre Hospito universitaire Franz Fanon   (Algeria)

^o ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^p A 1160 Vienna Austria   (Austria)

^q LINKÖPING UNIVERSITY   (Sweden)

^r SEMMELWEIS UNIVERSITY   (Hungary)

^s UNIVERSITY OF SHEFFIELD   (United Kingdom)

^t KLINIKUM LUDWIGSHAFEN   (Germany)

^u KERCKHOFF HEART CENTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; PLACEBO; TICAGRELOR; ADENOSINE; ANTICOAGULANT AGENT; CLOPIDOGREL; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY REPERFUSION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; ELECTROCARDIOGRAPHY; EMERGENCY CARE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; EMERGENCY HEALTH SERVICE; HEART INFARCTION; HEART MUSCLE REPERFUSION; MIDDLE AGED; MORTALITY;

ADENOSINE; AGED; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TIME-TO-TREATMENT;

EID: 84907048411     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407024     Document Type: Article

References (40)

1. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-31.
2. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-41.
3. Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 2010; 56: 1542-51.
4. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41.
5. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-13.
6. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
7. Herrmann HC, Lu J, Brodie BR, et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009; 2: 917-24.
8. Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial. Lancet 2008; 372: 537-46.
9. ten Berg JM, van 't Hof AW, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarc- tion on short- and long-term clinical outcome. J Am Coll Cardiol 2010; 55: 2446-55.
10. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009; 30: 2705-13.
11. Huber K, Holmes DR Jr, van 't Hof AW, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010; 31: 1708-16.
12. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
13. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with STelevation myocardial infarction. N Engl J Med 2008; 358: 2205-17.
14. Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101: 305-12.
15. Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308: 2507-16. [Erratum, JAMA 2013; 309: 1461.]
16. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-32.
17. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-62.
18. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.
19. Valgimigli M, Tebaldi M, Campo G, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5: 268-77.
20. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segmentelevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
21. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-6.
22. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-6.
23. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
24. Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs 2011; 71: 909-33.
25. Montalescot G, Lassen JF, Hamm CW, et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J 2013; 165: 515-22.
26. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283: 2686-92.
27. Westerhout CM, Bonnefoy E, Welsh RC, Steg PG, Boutitie F, Armstrong PW. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J 2011; 161: 283-90.
28. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292: 362-6.
29. De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data metaanalysis. Heart 2008; 94: 1548-58.
30. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297: 591-602.
31. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360: 2176-90.
32. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(23): e663-e828. [Erratum, Circulation 2013; 127(24): e863-e864.]
33. Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
34. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
35. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 2014 April 11 (Epub ahead of print).
36. Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128: 1055-65.
37. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374: 1149-59.
38. Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207-17.
39. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014 July 4 (Epub ahead of print).
40. Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther 2014; 19: 179-90.